Norchieung Health: Osimertinib Approved for Market in Australia by the Therapeutic Goods Administration.

Nuo Cheng Jianhua announcement, recently, the company received notification that Obutinib has been granted marketing authorization by the Australian Therapeutic Goods Administration. Obutinib is a novel BTK inhibitor developed independently by the company with high target selectivity, which can effectively avoid adverse reactions caused by off-target effects and significantly improve the safety and efficacy of treatment.